Mon, December 21, 2009
Fri, December 18, 2009
Thu, December 17, 2009
Wed, December 16, 2009
Tue, December 15, 2009
Mon, December 14, 2009
Fri, December 11, 2009
Thu, December 10, 2009
Wed, December 9, 2009
Tue, December 8, 2009
Mon, December 7, 2009
Sun, December 6, 2009
Fri, December 4, 2009
Thu, December 3, 2009
Wed, December 2, 2009
Tue, December 1, 2009
Mon, November 30, 2009
Fri, November 27, 2009
Thu, November 26, 2009
Wed, November 25, 2009
Tue, November 24, 2009
Mon, November 23, 2009
Sun, November 22, 2009
Fri, November 20, 2009
Thu, November 19, 2009
Wed, November 18, 2009
Tue, November 17, 2009
Mon, November 16, 2009
Sun, November 15, 2009
Fri, November 13, 2009
Thu, November 12, 2009
Wed, November 11, 2009
Tue, November 10, 2009
Mon, November 9, 2009
Fri, November 6, 2009
Thu, November 5, 2009
Wed, November 4, 2009
Tue, November 3, 2009

QLT announces MGH litigation settlement


  Copy link into your clipboard //health-fitness.news-articles.net/content/2009/11/25/qlt-announces-mgh-litigation-settlement.html
  Print publication without navigation Published in Health and Fitness on by Market Wire
          🞛 This publication is a summary or evaluation of another publication

VANCOUVER, Nov. 25 /CNW/ - QLT Inc. (NASDAQ: QLTI; TSX: QLT) ("QLT" or the "Company") today announced the settlement of its litigation with the General Hospital Corporation, doing business as Massachusetts General Hospital ("MGH"). Under the terms of the settlement agreement, QLT will pay US$20.0 million to MGH as payment in full for all past and future royalty obligations under the License Agreement between QLT and MGH, in exchange for the dismissal with prejudice of MGH's lawsuit against QLT pending in the Massachusetts District Court for violation of Massachusetts General Law Chapter 93A, sections 2 and 11. As part of the settlement, QLT and MGH have also released each other from any claims in connection with the lawsuit and certain related matters. Under the existing License Agreement, QLT was obligated to pay MGH a 0.5% royalty on Visudyne(R) sales in the U.S. and Canada.

"We are pleased to put this matter behind us and continue to concentrate on our clinical programs and strategic growth initiatives," said Bob Butchofsky, President and Chief Executive Officer of QLT. "We believe that this agreement fairly resolves our dispute and serves to recognize the critically important contributions made by MGH in the development of Visudyne."

About QLT

QLT Inc. is a pharmaceutical company dedicated to the development and commercialization of innovative therapies for the eye. We are focused on our commercial product Visudyne(R) for the treatment of wet-AMD, and the development of drugs to be delivered in our proprietary punctal plug devices. For more information, visit our website at [ www.qltinc.com ].

Visudyne is a registered trademark of Novartis AG.

QLT Inc. is listed on The NASDAQ Stock Market under the trading symbol "QLTI" and on the Toronto Stock Exchange under the trading symbol "QLT."


Publication Contributing Sources